Abstract
IT HAS been recognized that recipient lymphocytotoxic antibodies directed to organ donor lymphocytes are frequently associated with hyperacute rejection. Therefore, for many years it has been standard practice to perform a crossmatch test against donor lymphocytes before transplantation. We previously reported that double-filtration plasmapheresis (DFPP) was effective in removing preformed antibodies and led to encouraging results in presensitized patients. However, with cyclosporine A (CyA), the graft survival rate was lower in presensitized patients than in sero-negative patients. From May 1996, FK 506 (tacrolimus, Prograf) has been commercially available for renal transplantation in Japan. In this study, we analyzed the effects of FK 506 on the clinical course of transplantation in presensitized recipients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
